Eagle Pharmaceuticals, INC

Eagle Pharmaceuticals has amended its Rights Agreement to clarify the Board's authority, following its delisting from the Nasdaq.

Eagle Pharmaceuticals has dismissed Ernst & Young as its auditor and appointed BDO, following the need to restate several years of financial statements due to identified material weaknesses in internal controls.

Eagle Pharmaceuticals has announced its intention to delist from the Nasdaq and file a Form 25 with the SEC, completing its move to the OTC Expert Market.

Eagle Pharmaceuticals has appointed Christopher Krawtschuk as its new Chief Financial Officer, effective November 11, 2024, following the company's delisting from the Nasdaq.

Eagle Pharmaceuticals has adopted a limited duration stockholder rights plan to protect against hostile takeovers and ensure all stockholders can realize the long-term value of their investment.

Eagle Pharmaceuticals is facing delisting from Nasdaq due to accounting errors and delays in financial reporting, leading to a credit agreement default and a review of financing alternatives.

Scott Tarriff, a director at Eagle Pharmaceuticals, sold shares to cover tax obligations related to vesting restricted stock units.

Brian Cahill, CFO of Eagle Pharmaceuticals, reports the acquisition of 3,800 shares of common stock upon vesting of performance stock units and the subsequent withholding of 1,589 shares for tax obligations.

Scott Tarriff, an executive at Eagle Pharmaceuticals, reported the acquisition and disposition of company stock related to vesting performance stock units and tax liabilities.

J. Goldman & Co. LP, along with its affiliates, has reported a passive beneficial ownership of 5.1% in Eagle Pharmaceuticals, Inc. common stock.

Nantahala Capital Management, LLC and its managing members disclosed a significant beneficial ownership of 38.08% in Eagle Pharmaceuticals, Inc.

Nantahala Capital Partners Limited Partnership, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a passive beneficial ownership of 6.241% in Eagle Pharmaceuticals, Inc.

Nantahala Capital Management, along with its principals Wilmot B. Harkey and Daniel Mack, has reported a substantial 38.078% beneficial ownership stake in Eagle Pharmaceuticals, Inc. as of February 16, 2025.

Union Square Park Partners, LP and affiliated entities have reported a beneficial ownership of 11.44% in Eagle Pharmaceuticals, Inc. common stock as of December 31, 2024.